Table 5.
Name | Host | Dilution WB | Dilution if | Reference or source |
---|---|---|---|---|
Anti-ARL13 | rb | 1:25–250 | This study | |
Anti-IFT81 | mo | 1:1,000 | (Cole et al., 1998) | |
Anti-IFT139 | mo | 1:100 | (Cole et al., 1998) | |
Anti-IFT54 | rb | 1:100 | (Wingfield et al., 2017) | |
Anti-BBS1 | rb | 1:500 | (Xue et al., 2020) | |
Anti-BBS3 | rb | 1:2,000 | (Xue et al., 2020) | |
Anti-BBS4 | rb | 1:500 | (Lechtreck et al., 2009) | |
Anti-D1BLIC | rb | 1:2,000 | (Hou et al., 2004) | |
Anti-KAP | rt | 1:2,000 | Invitrogen, Carlsbad, CA | |
Anti-FMG1 | mo | 1:500 | (Bloodgood and Salomonsky, 1994) | |
Anti-PKD2 | rb | 1:3,000 | (Huang et al., 2007) | |
Anti-CAH6 | rb | 1:500 | (Yu et al., 2020) | |
Anti-FAP12 | rb | 1:1,000–2,500 | This study | |
Anti-PLD | rb | 1:1,000 | 1:80 | (Lechtreck et al., 2013) |
Anti-AMPK | rb | 1:1,000 | (Liu and Lechtreck, 2018) | |
Anti-PLC | rb | 1:3,000 | (Awasthi et al., 2012) | |
Anti-IC2 | mo | 1:1,000 | (King and Witman, 1990) | |
Anti-ac tubulin 6-11B-1 | mo | 1:1,000 | 1:800 | (LeDizet and Piperno, 1987); Sigma 32-2,700 |
Anti-GT335 | mo | 1:3,000 | (Wolff et al., 1992); AdipoGen AG-20B-0020-C100 |